Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost

Daptomycin remains as one of the main treatment options for Methicillin-Resistant Staphylococcus aureus (MRSA). Sporadic resistance cases reported in patients treated with either daptomycin or glycopeptides are a growing concern. In a previous study, we described a clinical case of a patient with a...

Full description

Bibliographic Details
Main Authors: Melanie Roch, Paula Gagetti, James Davis, Paola Ceriana, Laura Errecalde, Alejandra Corso, Adriana E. Rosato
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-12-01
Series:Frontiers in Microbiology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fmicb.2017.02303/full
_version_ 1819242048948011008
author Melanie Roch
Paula Gagetti
Paula Gagetti
James Davis
James Davis
Paola Ceriana
Laura Errecalde
Alejandra Corso
Adriana E. Rosato
author_facet Melanie Roch
Paula Gagetti
Paula Gagetti
James Davis
James Davis
Paola Ceriana
Laura Errecalde
Alejandra Corso
Adriana E. Rosato
author_sort Melanie Roch
collection DOAJ
description Daptomycin remains as one of the main treatment options for Methicillin-Resistant Staphylococcus aureus (MRSA). Sporadic resistance cases reported in patients treated with either daptomycin or glycopeptides are a growing concern. In a previous study, we described a clinical case of a patient with a community-acquired MRSA infection resistant to daptomycin and with intermediate resistance to vancomycin who developed a recurrent infection with a susceptible isogenic strain. In the present work, we further investigated the sequential events to determine whether the switch from a daptomycin resistance to a susceptible phenotype was due to a phenomenon of resistance reversion or recurrent infection with a susceptible strain. Pairwise competition experiments showed that the susceptible clinical recurrent SA6850 strain had increased fitness when compared to the resistant counterpart SA6820 strain. In fact, although we have demonstrated that reversion of daptomycin resistance to daptomycin susceptible can occur in vitro after serial passages in drug-free media, phylogenetic analysis suggested that the in vivo process was the result of a recurrent infection with a previous susceptible isolate carried by the patient rather than a resistance reversion of the strain. Whole genome sequence of evolved strains showed that daptomycin resistance in MRSA is associated with a high fitness cost mediated by mutations in mprF gene, revealed as a key element of the biological cost. Moreover, we determined that daptomycin resistance-associated fitness cost was independent of vancomycin intermediate resistance phenotype, as demonstrated in additional clinical MRSA vancomycin susceptible strains. This study highlights important observations as, despite daptomycin offers a useful treatment option for the patients with persistent infections, it has to be carefully monitored. The high fitness cost associated to daptomycin resistance may explain the reduced dissemination of daptomycin resistance and the absence of daptomycin reported outbreaks.
first_indexed 2024-12-23T14:33:37Z
format Article
id doaj.art-d3ec62596b924d0ca3c079e9de5edf01
institution Directory Open Access Journal
issn 1664-302X
language English
last_indexed 2024-12-23T14:33:37Z
publishDate 2017-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Microbiology
spelling doaj.art-d3ec62596b924d0ca3c079e9de5edf012022-12-21T17:43:25ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2017-12-01810.3389/fmicb.2017.02303309849Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness CostMelanie Roch0Paula Gagetti1Paula Gagetti2James Davis3James Davis4Paola Ceriana5Laura Errecalde6Alejandra Corso7Adriana E. Rosato8Department of Pathology and Genomic Medicine, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, TX, United StatesDepartment of Pathology and Genomic Medicine, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, TX, United StatesServicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, Administración Nacional de Laboratorios e Institutos de Salud, Buenos Aires, ArgentinaArgonne National Laboratory (DOE), Lemont, IL, United StatesComputation Institute, University of Chicago, Chicago, IL, United StatesServicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, Administración Nacional de Laboratorios e Institutos de Salud, Buenos Aires, ArgentinaDepartamento de Microbiologia, Hospital General de Agudos Juan Fernandez, Buenos Aires, ArgentinaServicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, Administración Nacional de Laboratorios e Institutos de Salud, Buenos Aires, ArgentinaDepartment of Pathology and Genomic Medicine, Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist Research Institute, Houston, TX, United StatesDaptomycin remains as one of the main treatment options for Methicillin-Resistant Staphylococcus aureus (MRSA). Sporadic resistance cases reported in patients treated with either daptomycin or glycopeptides are a growing concern. In a previous study, we described a clinical case of a patient with a community-acquired MRSA infection resistant to daptomycin and with intermediate resistance to vancomycin who developed a recurrent infection with a susceptible isogenic strain. In the present work, we further investigated the sequential events to determine whether the switch from a daptomycin resistance to a susceptible phenotype was due to a phenomenon of resistance reversion or recurrent infection with a susceptible strain. Pairwise competition experiments showed that the susceptible clinical recurrent SA6850 strain had increased fitness when compared to the resistant counterpart SA6820 strain. In fact, although we have demonstrated that reversion of daptomycin resistance to daptomycin susceptible can occur in vitro after serial passages in drug-free media, phylogenetic analysis suggested that the in vivo process was the result of a recurrent infection with a previous susceptible isolate carried by the patient rather than a resistance reversion of the strain. Whole genome sequence of evolved strains showed that daptomycin resistance in MRSA is associated with a high fitness cost mediated by mutations in mprF gene, revealed as a key element of the biological cost. Moreover, we determined that daptomycin resistance-associated fitness cost was independent of vancomycin intermediate resistance phenotype, as demonstrated in additional clinical MRSA vancomycin susceptible strains. This study highlights important observations as, despite daptomycin offers a useful treatment option for the patients with persistent infections, it has to be carefully monitored. The high fitness cost associated to daptomycin resistance may explain the reduced dissemination of daptomycin resistance and the absence of daptomycin reported outbreaks.http://journal.frontiersin.org/article/10.3389/fmicb.2017.02303/fullMRSAdaptomycinbiological costin vivo
spellingShingle Melanie Roch
Paula Gagetti
Paula Gagetti
James Davis
James Davis
Paola Ceriana
Laura Errecalde
Alejandra Corso
Adriana E. Rosato
Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost
Frontiers in Microbiology
MRSA
daptomycin
biological cost
in vivo
title Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost
title_full Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost
title_fullStr Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost
title_full_unstemmed Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost
title_short Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost
title_sort daptomycin resistance in clinical mrsa strains is associated with a high biological fitness cost
topic MRSA
daptomycin
biological cost
in vivo
url http://journal.frontiersin.org/article/10.3389/fmicb.2017.02303/full
work_keys_str_mv AT melanieroch daptomycinresistanceinclinicalmrsastrainsisassociatedwithahighbiologicalfitnesscost
AT paulagagetti daptomycinresistanceinclinicalmrsastrainsisassociatedwithahighbiologicalfitnesscost
AT paulagagetti daptomycinresistanceinclinicalmrsastrainsisassociatedwithahighbiologicalfitnesscost
AT jamesdavis daptomycinresistanceinclinicalmrsastrainsisassociatedwithahighbiologicalfitnesscost
AT jamesdavis daptomycinresistanceinclinicalmrsastrainsisassociatedwithahighbiologicalfitnesscost
AT paolaceriana daptomycinresistanceinclinicalmrsastrainsisassociatedwithahighbiologicalfitnesscost
AT lauraerrecalde daptomycinresistanceinclinicalmrsastrainsisassociatedwithahighbiologicalfitnesscost
AT alejandracorso daptomycinresistanceinclinicalmrsastrainsisassociatedwithahighbiologicalfitnesscost
AT adrianaerosato daptomycinresistanceinclinicalmrsastrainsisassociatedwithahighbiologicalfitnesscost